Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin Alfa with Chemoradiotherapy in NSCLC
NCT00028938Phase 3Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2002
- Primary completion
- Nov 2002
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epoetin alfa in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Time to local progression. Started Jan 2002; status: completed.
02
Drugs
epoetin alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00028938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00028938.